Aclaris Therapeutics (ACRS) Other Accumulated Expenses (2014 - 2026)

Aclaris Therapeutics' Other Accumulated Expenses history runs 13 years deep, the most recent figure standing at $2.8 million for Q1 2026.

• On a quarterly basis, Other Accumulated Expenses rose 2.63% year-over-year to $2.8 million in Q1 2026; TTM through Mar 2026 was $2.8 million, a 2.63% increase from a year earlier, with the FY2025 full-year figure at $504000.0, down 17.24% from the prior year.
• Other Accumulated Expenses climbed to $2.8 million in Q1 2026 per ACRS's latest filing, from $504000.0 in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $2.8 million in Q1 2026 and bottomed at $217000.0 in Q4 2022.
• The 5-year median for Other Accumulated Expenses is $1.7 million (2022), against an average of $1.5 million.
• Across the five-year window, Other Accumulated Expenses slumped 87.49% in 2022 and surged 1111.06% in 2023, its largest moves.
• Year by year, Other Accumulated Expenses stood at $217000.0 in 2022, then jumped by 1111.06% to $2.6 million in 2023, then plunged by 76.83% to $609000.0 in 2024, then decreased by 17.24% to $504000.0 in 2025, then surged by 449.8% to $2.8 million in 2026.
• Per Business Quant, the three latest ACRS Other Accumulated Expenses figures stand at $2.8 million (Q1 2026), $504000.0 (Q4 2025), and $387000.0 (Q3 2025).